These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31848813)

  • 1. Micropapillary Predominant Lung Adenocarcinoma in Stage IA Benefits from Adjuvant Chemotherapy.
    Wang C; Yang J; Lu M
    Ann Surg Oncol; 2020 Jun; 27(6):2051-2060. PubMed ID: 31848813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of postoperative adjuvant therapy on EGFR-mutated stage IA lung adenocarcinoma with micropapillary pathological subtypes.
    Cheng R; Hao Z; Qiu L; Zheng X; Huang S; Xian J; Huang H; Li J; Zhang Z; Ye K; Wu W; Zhang Y; Liu J
    World J Surg Oncol; 2024 Sep; 22(1):235. PubMed ID: 39232762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma.
    Qian F; Yang W; Wang R; Xu J; Wang S; Zhang Y; Jin B; Yu K; Han B
    J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1227-1235.e2. PubMed ID: 29223834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Chemotherapy Improves the Probability of Freedom From Recurrence in Patients With Resected Stage IB Lung Adenocarcinoma.
    Hung JJ; Wu YC; Chou TY; Jeng WJ; Yeh YC; Hsu WH
    Ann Thorac Surg; 2016 Apr; 101(4):1346-53. PubMed ID: 26794883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance and survival benefits of postoperative adjuvant chemotherapy in patients with stage IA lung adenocarcinoma with non-predominant micropapillary components.
    Li R; Qiu J; Li Z; Li H; Tang Z; Yu W; Tian H; Sun Z
    World J Surg Oncol; 2024 Jan; 22(1):32. PubMed ID: 38273367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma.
    Murakami S; Ito H; Tsubokawa N; Mimae T; Sasada S; Yoshiya T; Miyata Y; Yokose T; Okada M; Nakayama H
    Lung Cancer; 2015 Nov; 90(2):199-204. PubMed ID: 26341957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of surgery and adjuvant chemotherapy on the survival of stage I lung adenocarcinoma patients with tumor spread through air spaces.
    Lv Y; Li S; Liu Z; Ren Z; Zhao J; Tao G; Zheng Z; Han Y; Ye B
    Lung Cancer; 2023 Mar; 177():51-58. PubMed ID: 36736075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative prognostic influence of micropapillary pattern in stage IA lung adenocarcinoma.
    Tsubokawa N; Mimae T; Sasada S; Yoshiya T; Mimura T; Murakami S; Ito H; Miyata Y; Nakayama H; Okada M
    Eur J Cardiothorac Surg; 2016 Jan; 49(1):293-9. PubMed ID: 25762400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome.
    Cha MJ; Lee HY; Lee KS; Jeong JY; Han J; Shim YM; Hwang HS
    J Thorac Cardiovasc Surg; 2014 Mar; 147(3):921-928.e2. PubMed ID: 24199757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological features, survival outcomes, and appropriate surgical approaches for stage I acinar and papillary predominant lung adenocarcinoma.
    Lu D; Yang J; Liu X; Feng S; Dong X; Shi X; Zhai J; Mai S; Jiang J; Wang Z; Wu H; Cai K
    Cancer Med; 2020 May; 9(10):3455-3462. PubMed ID: 32207885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of Lepidic Component Predominance to Adjuvant Chemotherapy with Oral Fluoropyrimidines for Stage I Lung Adenocarcinoma.
    Sasada S; Miyata Y; Mimae T; Tsutani Y; Mimura T; Okada M
    Clin Lung Cancer; 2016 Sep; 17(5):433-440.e1. PubMed ID: 26725850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Lepidic Component Occupancy on Effects of Adjuvant Chemotherapy for Lung Adenocarcinoma.
    Sasada S; Miyata Y; Mimae T; Mimura T; Okada M
    Ann Thorac Surg; 2015 Dec; 100(6):2079-86. PubMed ID: 26298165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Could tumor spread through air spaces benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-institutional study.
    Chen D; Wang X; Zhang F; Han R; Ding Q; Xu X; Shu J; Ye F; Shi L; Mao Y; Chen Y; Chen C
    Ther Adv Med Oncol; 2020; 12():1758835920978147. PubMed ID: 33403018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival benefit of adjuvant chemotherapy after resection of Stage I lung adenocarcinoma containing micropapillary components.
    Li Y; Zhao J; Zhao Y; Li R; Dong X; Yao X; Xia Z; Xu Y; Li Y
    Cancer Med; 2024 Feb; 13(3):e7030. PubMed ID: 38400663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the presence of a micropapillary component predict worse prognosis in pathological stage IA lung adenocarcinoma?
    Wang Y; Song W; Wang X; Che G
    Pathol Res Pract; 2023 Feb; 242():154314. PubMed ID: 36706587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB.
    Luo J; Huang Q; Wang R; Han B; Zhang J; Zhao H; Fang W; Luo Q; Yang J; Yang Y; Zhu L; Chen T; Cheng X; Wang Y; Zheng J; Wu H; Xia W; Chen H
    J Cancer Res Clin Oncol; 2016 Sep; 142(9):2031-40. PubMed ID: 27379889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for lymph node negative stage I and IIA non-small cell lung cancer: multicenter experiences.
    Oven Ustaalioglu BB; Unal OU; Turan N; Bilici A; Kaya S; Eren T; Ulas A; Inal A; Berk V; Demirci U; Alici S; Bal O; Benekli M; Gumus M
    Asian Pac J Cancer Prev; 2013; 14(11):6287-92. PubMed ID: 24377519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of adjuvant chemotherapy on survival of patients with stage IB non-small cell lung cancer with visceral pleural invasion.
    Xie J; Zhang X; Hu S; Peng WD; Xu B; Li Y; Zhang SJ; Li Q; Li C
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2231-2239. PubMed ID: 32533405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
    Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
    Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive Value of Recurrence of Solid and Micropapillary Subtypes in Lung Adenocarcinoma.
    Motono N; Mizoguchi T; Ishikawa M; Iwai S; Iijima Y; Uramoto H
    Oncology; 2024; 102(4):366-373. PubMed ID: 37899040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.